Surgery and durvalumab after chemoradiotherapy for hard-to-operate lung cancer
Tests surgery then durvalumab after chemoradiotherapy in adults with non-small cell lung cancer.
Key facts
- Who runs it
- Amsterdam UMC Stichting
- Where
- Amsterdam, NetherlandsSee the site
- Trial code
- Registry title
- ChemoRadiotherapy with Or Without surgery followed by consolidation Durvalumab (CROWD): a phase IV feasibility trial
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 38 people enrolled
- Started
- 16 Dec 2024
- Ended
- 13 Nov 2026
- Type of study
- Interventional
- Record updated
- 12 December 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with stage III non-small cell lung cancer (not N3) who are first planned for chemoradiotherapy followed by durvalumab. It tests whether surgery after chemoradiotherapy is safe.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Stage III non-small cell lung cancer without N3 disease, confirmed by tissue or cell tests before chemoradiotherapy starts
- Earlier treatment
- The team first advised chemoradiotherapy followed by durvalumab, without surgery. People must not have had chemoradiotherapy schemes other than platinum doublet with 30 once-daily fractions of 2 Gy.
- Biomarker or test result
- If N2 disease is suspected, invasive staging of the mediastinum must prove it before chemoradiotherapy starts. People with known gene changes that can be treated cannot join.
Main reasons for not taking part
- TxN3 or M1 disease
- Chemoradiotherapy schemes other than platinum doublet with 30 once-daily fractions of 2 Gy
- Cannot have surgery because of heart and lung function tests or other illnesses
- Known gene changes that can be treated with targeted drugs
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Histologically or cytologically confirmed stage III (non-N3) NSCLC (TNM 8th edition), before start of chemoradiotherapy
- In case of suspected N2-disease, mediastinal invasive staging (EUS, EBUS and/or mediastinoscopy) to prove N2 involvement before start of concurrent CRT is mandatory
- Initial MDT recommendation for a non-surgical treatment comprising CRT followed by durvalumab
Who cannot take part
- Patients with TxN3 or M1 disease
- The use of any CRT schemes other than those in ESMO recommendations (platinum doublet, 30 once-daily fractions of 2 Gy)
- Patients deemed inoperable based on cardiopulmonary function tests or comorbidity
- Patients with known actionable genomic alterations
Where in Netherlands
- Amsterdam UMC StichtingAmsterdam, NetherlandsNo longer taking part
About the trial
What the trial wants to find out
-to assess the safety of surgery in patients with initially unresectable stage III NSCLC who are considered resectable by the multidisciplinary team within 12 weeks after finishing high-dose CRT -to assess the ability to proceed to durvalumab consolidation therapy after surgery
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- ChemoRadiotherapy with Or Without surgery followed by consolidation Durvalumab (CROWD): a phase IV feasibility trial
- Plain-language title
- Surgery and durvalumab after chemoradiotherapy for hard-to-operate lung cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 12 December 2024